COVID-19 and liver disease: An update

Téllez, Luís; Mateos, Rosa María Martín

doi:10.1016/j.gastre.2020.06.005

Cited by 27 publications

(25 citation statements)

References 51 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are studies which demonstrated that presence of comorbid conditions such as liver cirrhosis in patients with COVID-19 was associated with worse prognosis [131,132]. A multi-center international study of 103 COVID-19 patients with cirrhosis and 49 noncirrhotics conducted in early 2020 found that those individuals who developed liver decompensation during the COVID-19 illness had increased risk of death compared with those devoid of hepatic compensation (63.2% vs. 26.2%) [133].…”

Section: Interconnection Between Sars-cov-2 Infection and Preexisting Liver Co-morbidity 71 Chronic Liver Disease And Cirrhosismentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

et al. 2021

View full text Add to dashboard Cite

Globally, millions of persons have contracted the coronavirus disease 2019 (COVID-19) over the past several months, resulting in significant mortality. Health care systems are negatively impacted including the care of individuals with cancers and other chronic diseases such as chronic active hepatitis, cirrhosis and hepatocellular carcinoma. There are various probable pathogenic mechanisms that have been presented to account for liver injury in COVID-19 patients such as hepatotoxicity cause by therapeutic drugs, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the bile duct cells and hepatocytes, hypoxia and systemic inflammatory response. Liver biochemistry tests such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) are deranged in COVID-19 patients with liver injury. Hepatocellular damage results in the elevation of serum AST and ALT levels in early onset disease while a cholestatic pattern that develops as the disease progress causes higher levels of ALP, GGT, direct and total bilirubin. These liver biochemistry tests are prognostic markers of disease severity and should be carefully monitored in COVID-19 patients. We conducted a systematic review of abnormal liver biochemistry tests in COVID-19 and the possible pathogenesis involved. Significant findings regarding the severity, hepatocellular pattern, incidence and related clinical outcomes in COVID-19 patients are highlighted.

show abstract

Section: Interconnection Between Sars-cov-2 Infection and Preexisting Liver Co-morbidity 71 Chronic Liver Disease And Cirrhosismentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There are studies which demonstrated that presence of comorbid conditions such as liver cirrhosis in patients with COVID-19 was associated with a worse prognosis [157,158]. A multicenter international study of 103 COVID-19 patients with cirrhosis and 49 non-cirrhotics conducted in early 2020 found that those individuals who developed liver decompensation during the COVID-19 illness had increased risk of death compared with those devoid of hepatic compensation (63.2% vs 26.2%) [159].…”

Section: Chronic Liver Disease and Cirrhosismentioning

confidence: 99%

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

McGrowder

Miller

Cross

et al. 2021

Preprint

View full text Add to dashboard Cite

Globally, over the past several months millions of persons contracted the coronavirus disease 2019 (COVID-19) resulting in significant mortality. Health care systems are negatively impacted including the care of individuals with cancers and other chronic diseases such as chronic active hepatitis, cirrhosis and hepatocellular carcinoma. There are various probable pathogenic mechanisms that have been presented to account for liver injury in COVID-19 patients such as hepatotoxicity cause by therapeutic drugs, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the bile duct cells and hepatocytes, hypoxia and systemic inflammatory response. Liver biochemistry tests such as AST, ALT, GGT and ALP are deranged in COVID-19 patients with liver injury. Hepatocellular damage results in the elevation of serum AST and ALT levels in early onset disease while a cholestatic pattern that develops as the disease progress causes higher levels of ALP, GGT, direct and total bilirubin. These liver biochemistry tests are prognostic markers of disease severity and should be carefully monitored in COVID-19 patients. We conducted a systematic review of abnormal liver biochemistry tests in COVID-19 and the possible pathogenesis involved. Significant findings regarding the severity, hepatocellular pattern, incidence and related clinical outcomes in COVID-19 patients are highlighted.

show abstract

“…In addition, hepatotoxicity is more pronounced in patients with severe COVID-19, which can be caused by systemic inflammation, liver damage from medications used to treat COVID-19, or preexisting chronic liver disease. Previous studies suggest that liver damage associated with COVID-19 is usually rare, and damage to this tissue is secondary to pneumonia resulting from the disease and the length of hospitalization (1)(2)(3)(4). Therefore, according to the mentioned explanations, the present mini-review study investigated the effect of COVID-19 on hepatic damages and its cellular mechanism of action.…”

Section: Contextmentioning

confidence: 97%

Role of COVID-19 in Hepatic Damage and Its Cellular Entrance and Mechanism of Action: A Mini-Review

Oroojan

2021

Trends in Med Sci

View full text Add to dashboard Cite

Context: COVID-19 induces damage to the liver in addition to the pulmonary system. This event can alter hepatic biochemical and histological variables. Therefore, the present mini-review study investigated the effect of COVID-19 on hepatic damages and its cellular mechanism of action. Evidence Acquisition: In this mini-review study, the effects of COVID-19 on liver cells were sought in PubMed without restriction. The related components were searched in the Me SH term system and also used in two groups of COVID-19 and hepatocytes in combination with each other. Then, the titles and abstracts of the selected articles were assessed, and unrelated articles were removed. Results and Conclusion: COVID-19 leads to liver tissue damage and hepatocyte apoptosis by inducing increased cytokines, ischemia, and hepatic hypoxia following cardiorespiratory failure, coagulation disorders, and intracellular calcium. The SARS-CoV-2 virus exerts this effect through the ACE2 receptor and increasing its expression in cholangiocytes.

show abstract

COVID-19 and liver disease: An update

Cited by 27 publications

References 51 publications

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

Role of COVID-19 in Hepatic Damage and Its Cellular Entrance and Mechanism of Action: A Mini-Review

Contact Info

Product

Resources

About